Targeting the metabolic pathways and substrates that cancer cells rely on can be a potential therapeutic strategy. Inhibitors of glycolytic enzymes, for instance, can limit the availability of critical substrates, impeding cancer cell growth. Drugs targeting the TCA cycle or amino acid metabolism also show promise in disrupting the metabolic flexibility of cancer cells.
